Serum leukotriene B4 and hydroxyeicosatetraenoic acid in the prediction of pre-eclampsia
Copyright © 2020 Elsevier Ltd. All rights reserved..
INTRODUCTION: Pre-eclampsia (PE) affects 2-8% of pregnancies worldwide. Despite identification of numerous possible biomarkers, accurate prediction and early diagnosis of PE remain challenging. We examined the potential of leukotriene B4 (LTB4) and 15-hydroxyeicosatetraenoic acid (15(S)-HETE) as biomarkers of PE by comparing serum levels at three gestational age (GA) groups between normotensive pregnancies and asymptomatic women who subsequently developed preterm or term-PE.
METHODS: This is a case-control study drawn from a prospective study of adverse pregnancy outcomes with serum samples collected at 19-24 weeks (n = 48), 30-34 weeks (n = 101) and 35-37 weeks (n = 54) GA. LTB4 and 15(S)-HETE levels were determined by ELISA. Serum level multiples of the median (MoM) were compared between normal and PE-pregnancies. Association between LTB4 and 15(S)-HETE and GA at delivery was investigated with Cox proportional-hazards models.
RESULTS: Serum LTB4 levels were lower in women of East-Asian ethnicity, higher in women with PE history, and increased with GA in normotensive pregnancies, but not in PE. LTB4 was elevated at 19-24 weeks in women who developed preterm-PE. There was a negative association between LTB4 MoM and interval between sampling and delivery with PE at 19-24 weeks only. Serum 15(S)-HETE levels were not influenced by GA at testing and were elevated in women of South-Asian ethnicity. Median 15(S)-HETE levels were unchanged in preterm and term-PE at any GA.
DISCUSSION: LTB4 was higher at 19-24 weeks in pregnancies that developed preterm-PE versus unaffected pregnancies, suggesting it is a potentially useful predictive marker of preterm PE in the second trimester.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Placenta - 103(2021) vom: 01. Jan., Seite 76-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santos, Leilani L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15(S)-HETE |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.placenta.2020.10.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316680338 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316680338 | ||
| 003 | DE-627 | ||
| 005 | 20231225161619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.placenta.2020.10.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316680338 | ||
| 035 | |a (NLM)33099202 | ||
| 035 | |a (PII)S0143-4004(20)30394-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santos, Leilani L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum leukotriene B4 and hydroxyeicosatetraenoic acid in the prediction of pre-eclampsia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Pre-eclampsia (PE) affects 2-8% of pregnancies worldwide. Despite identification of numerous possible biomarkers, accurate prediction and early diagnosis of PE remain challenging. We examined the potential of leukotriene B4 (LTB4) and 15-hydroxyeicosatetraenoic acid (15(S)-HETE) as biomarkers of PE by comparing serum levels at three gestational age (GA) groups between normotensive pregnancies and asymptomatic women who subsequently developed preterm or term-PE | ||
| 520 | |a METHODS: This is a case-control study drawn from a prospective study of adverse pregnancy outcomes with serum samples collected at 19-24 weeks (n = 48), 30-34 weeks (n = 101) and 35-37 weeks (n = 54) GA. LTB4 and 15(S)-HETE levels were determined by ELISA. Serum level multiples of the median (MoM) were compared between normal and PE-pregnancies. Association between LTB4 and 15(S)-HETE and GA at delivery was investigated with Cox proportional-hazards models | ||
| 520 | |a RESULTS: Serum LTB4 levels were lower in women of East-Asian ethnicity, higher in women with PE history, and increased with GA in normotensive pregnancies, but not in PE. LTB4 was elevated at 19-24 weeks in women who developed preterm-PE. There was a negative association between LTB4 MoM and interval between sampling and delivery with PE at 19-24 weeks only. Serum 15(S)-HETE levels were not influenced by GA at testing and were elevated in women of South-Asian ethnicity. Median 15(S)-HETE levels were unchanged in preterm and term-PE at any GA | ||
| 520 | |a DISCUSSION: LTB4 was higher at 19-24 weeks in pregnancies that developed preterm-PE versus unaffected pregnancies, suggesting it is a potentially useful predictive marker of preterm PE in the second trimester | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 15(S)-HETE | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Eicosanoids | |
| 650 | 4 | |a LTB4 | |
| 650 | 4 | |a Leukotriene | |
| 650 | 4 | |a Pre-eclampsia | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Hydroxyeicosatetraenoic Acids |2 NLM | |
| 650 | 7 | |a Leukotriene B4 |2 NLM | |
| 650 | 7 | |a 1HGW4DR56D |2 NLM | |
| 700 | 1 | |a Wertaschnigg, Dagmar |e verfasserin |4 aut | |
| 700 | 1 | |a Rolnik, Daniel L |e verfasserin |4 aut | |
| 700 | 1 | |a Da Silva Costa, Fabricio |e verfasserin |4 aut | |
| 700 | 1 | |a Syngelaki, Argyro |e verfasserin |4 aut | |
| 700 | 1 | |a Dimitriadis, Evdokia |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolaides, Kypros H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Placenta |d 1987 |g 103(2021) vom: 01. Jan., Seite 76-81 |w (DE-627)NLM012770787 |x 1532-3102 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2021 |g day:01 |g month:01 |g pages:76-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.placenta.2020.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2021 |b 01 |c 01 |h 76-81 | ||